Primary antimitochondrial activity of the cancer drug methylglyoxal bis(guanylhydrazone) in yeast cells.
Primary action of methylglyoxal bis(guanylhydrazone) (MGBG) on the yeast mitochondrial system was demonstrated by (1) selective inhibition of cell growth in non-fermentable medium, (2) blockage of mitochondrial synthesis of cytochromes aa3 and b and (3) ultrastructural aberration. The drug caused extensive deletions in mitochondrial DNA detected by an increase in the frequency of the mitochondrial mutant petite but had little or no effect on cell viability. Growth inhibition by MGBG had any effect on growth inhibition by ethidium bromide. Strains showed no cross-correlation in their tolerance to MGBG and ethidium bromide.
D004261:DNA Replication / Q000187:drug effects; D005656:Fungal Proteins / Q000096:biosynthesis; D006146:Guanidines / Q000494:pharmacology*; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D008935:Mitoguazone / Q000494:pharmacology*; D010101:Oxygen Consumption / Q000187:drug effects; D012441:Saccharomyces cerevisiae / Q000187:drug effects* / Q000648:ultrastructure
D005656:Fungal Proteins; D006146:Guanidines; D008935:Mitoguazone